Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

he requirements and plans for regulatory filings and approvals for clofarabine in additional indications. These risks and uncertainties include, among others, the timing and results of clinical studies for clofarabine; the timing of discussions with the EMEA and FDA regarding clinical study results and approval of clofarabine in additional indications; the timing and content of decisions by the EMEA and FDA related to clinical trials and approval of clofarabine in additional indications; the actual efficacy and safety of clofarabine for the indications in which it is being tested; and the risks and uncertainties described in reports filed by Genzyme with the U.S. Securities and Exchange Commission, including without limitation the factors discussed under the caption "Risk Factors" in Genzyme's Annual Report on Form 10-K for the year ended December 31, 2007. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Genzyme(R) and Evoltra(R) are registered trademarks of Genzyme Corporation or its subsidiaries. All rights reserved.

Media Contact: Investor Contact:

Maria Cantor Patrick Flanigan

(617) 768-6690 (617) 768-6563


'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Jolla, CA (PRWEB) July 23, 2014 ... stem cell therapy in the US aimed at improving ... announced their newest clinical study for Parkinson’s disease. ... efficacy of stem cell therapy are paramount when providing ... This clinical study makes stem cell therapy accessible to ...
(Date:7/23/2014)... TEL AVIV, Israel , July 23, 2014 ... Ltd ., a portfolio company of Trendlines ... with one of Israel,s ... (Logo: http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines ... from plant pulp waste, with additional nanoparticles to ...
(Date:7/23/2014)... 2014 DuPont Pioneer announced today that ... president of Agricultural Biotechnology (ABT), effective July 21, 2014. ... most recently as president, chief executive officer and board ... in the seed and crop protection industry to this ... Schickler , president of DuPont Pioneer. “I am looking ...
(Date:7/23/2014)... 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... sustainable chemicals, today announced that the underwriters of its ... to purchase an additional 420,000 shares of common ... per share, less underwriting discounts and commissions, in ... of 2,800,000 shares of common stock, bringing the ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
...  inVentiv Health, Inc., offering best-in-class clinical, commercial and ... it has completed the acquisition of Kforce Clinical ... solutions to pharmaceutical, biotech and medical device companies, ... The transaction closed on March 30, 2012.  ...
... 3, 2012 Health Diagnostic Laboratory, Inc. (HDL, Inc.), ... of Scott Blackwell. Recently named Vice President of Corporate ... values of an advanced laboratory that is growing on ... http://photos.prnewswire.com/prnh/20120403/PH81634 )  "Scott comes to our ...
... N.J., April 3, 2012 Hamamatsu Corporation announces ... distributed through third-party dealers, will now be available ... the company is responsible for the sales, marketing, ... product line for new customers throughout North America. ...
Cached Biology Technology:inVentiv Health Completes Acquisition of Kforce Clinical Research 2inVentiv Health Completes Acquisition of Kforce Clinical Research 3inVentiv Health Completes Acquisition of Kforce Clinical Research 4Health Diagnostic Laboratory Names Scott Blackwell Vice President of Corporate Culture 2Hamamatsu Corporation Announces Exclusive Distribution of Its NanoZoomer Whole-Slide Scanners 2
(Date:7/23/2014)... ischemic preconditioning has been confirmed by many studies, ... study released in the Neural Regeneration Research ... Liu and co-workers from Tongji Hospital Affiliated to ... Technology, China performed cerebral ischemic preconditioning in rats ... the mechanism underlying the neuroprotective effect of ischemic ...
(Date:7/23/2014)... release is available in German . ... the Max Planck Institute of Molecular Cell Biology ... to capture detailed three-dimensional images of cardiac dynamics ... Selective Plane Illumination Microscopy (SPIM) and clever image ... beating heart. Furthermore, they have developed a method ...
(Date:7/22/2014)... July 22, 2014 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... 2014 was $6.8 million, an increase of 53% compared to ... before patent related income in the second quarter of 2014 ... quarter of 2013. The increase in revenue and operating income ...
Breaking Biology News(10 mins):Unbreak my heart 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... American Association for Cancer Research will recognize 27 recipients of ... at the AACR 102nd Annual Meeting 2011, held here from ... AACR-Thomas J. Bardos Science Education Award for Undergraduate Students is ... the field of cancer research. The AACR is committed ...
... William Hamilton introduced Inclusive Fitness Theory to predict and ... gene expression. With its many successes, the theory became ... Harvard researchers challenged the theory in the prestigious journal, ... scores of scientists, including Edward Allen Herre and William ...
... March 25, 2011 The Barrett-Jackson Collector Car Auction in ... through the sale and resale of a special ... the 40th anniversary sports car (the first Corvette was made ... it could be sold Jan. 22 at Barrett-Jackson,s 40th anniversary ...
Cached Biology News:AACR awards AACR-Thomas J. Bardos Science Education Award for Undergraduate Students 2AACR awards AACR-Thomas J. Bardos Science Education Award for Undergraduate Students 3Is blood thicker than water? 2Sale of sports car benefits TGen cancer fund named for Jackson family 2
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
...
... Kit contains choice of PDMS Stamps (3 ... / 200 micron squares or 100 um ... 10 mm lines, 3 PDMS nano-patterned stamps ... nm and pitch of 400 nm, or ...
...
Biology Products: